Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Stoke Therapeutics Inc (NASDAQ: STOK) closed the day trading at $22.86 up 1.74% from the previous closing price of $22.47. In other words, the price has increased by $1.74 from its previous closing price. On the day, 1.06 million shares were traded. STOK stock price reached its highest trading level at $23.35 during the session, while it also had its lowest trading level at $21.68.
Ratios:
For a better understanding of STOK, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.93. For the most recent quarter (mrq), Quick Ratio is recorded 6.53 and its Current Ratio is at 6.53. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 ’25 when Ticho Barry sold 5,931 shares for $25.72 per share. The transaction valued at 152,566 led to the insider holds 7,195 shares of the business.
BARUCH TICHO bought 5,931 shares of STOK for $178,167 on Nov 03 ’25. On Oct 08 ’25, another insider, Kaye Edward M. MD, who serves as the Director of the company, sold 25,000 shares for $30.00 each. As a result, the insider received 750,000 and left with 49,124 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1305698176 and an Enterprise Value of 1062170048. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.35 while its Price-to-Book (P/B) ratio in mrq is 4.09. Its current Enterprise Value per Revenue stands at 5.165 whereas that against EBITDA is 36.517.
Stock Price History:
The Beta on a monthly basis for STOK is 1.20, which has changed by 0.6553222 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $38.69, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is -13.62%, while the 200-Day Moving Average is calculated to be 55.63%.
Shares Statistics:
Over the past 3-months, STOK traded about 1.19M shares per day on average, while over the past 10 days, STOK traded about 1234360 shares per day. A total of 55.12M shares are outstanding, with a floating share count of 49.09M. Insiders hold about 14.06% of the company’s shares, while institutions hold 109.58% stake in the company. Shares short for STOK as of 1760486400 were 10831308 with a Short Ratio of 9.08, compared to 1757894400 on 11386332. Therefore, it implies a Short% of Shares Outstanding of 10831308 and a Short% of Float of 23.9.
Earnings Estimates
. The current assessment of Stoke Therapeutics Inc (STOK) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.63 and low estimates of -$0.76.
Analysts are recommending an EPS of between $0.04 and $0.04 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is -$2.9, with 8.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
9 analysts predict $4.87M in revenue for. The current quarter. It ranges from a high estimate of $7M to a low estimate of $3M. As of. The current estimate, Stoke Therapeutics Inc’s year-ago sales were $22.61M
A total of 5 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $190M, while the lowest revenue estimate was $186.02M, resulting in an average revenue estimate of $187.97M. In the same quarter a year ago, actual revenue was $36.55M
